Title
Emerging drugs for head and neck cancer

Permalink
https://escholarship.org/uc/item/971393f1

Journal
Expert Opinion on Emerging Drugs, 20(2)

ISSN
1472-8214

Authors
Wen, Y
Grandis, JR

Publication Date
2015-06-01

DOI
10.1517/14728214.2015.1031653

Peer reviewed
Emerging drugs for head and neck cancer

Yihui Wen & Jennifer R Grandis

To cite this article: Yihui Wen & Jennifer R Grandis (2015) Emerging drugs for head and neck cancer, Expert Opinion on Emerging Drugs, 20:2, 313-329, DOI: 10.1517/14728214.2015.1031653

To link to this article: http://dx.doi.org/10.1517/14728214.2015.1031653

Published online: 31 Mar 2015.

Submit your article to this journal

Article views: 344

View related articles

View Crossmark data
Emerging drugs for head and neck cancer

Yihui Wen & Jennifer R Grandis

University of California, Clinical and Translational Science Institute, Department of Otolaryngology-Head and Neck Surgery, San Francisco, CA, USA

Introduction: Despite improvements in treatment, survival rates of head and neck squamous cell carcinoma (HNSCC) are stagnant. The existing chemotherapeutic agents are non-selective and associated with toxicities. Combinations of the only the US FDA-approved epidermal growth factor receptor (EGFR)-targeted agent, cetuximab, with chemotherapy or radiation improves overall survival. However, the response rates to cetuximab are modest. Thus, there is an urgent need for new agents that can be safely integrated into current treatment regimens to improve outcome.

Areas covered: Current EGFR-targeted drugs under clinical development include mAbs and tyrosine kinase inhibitors. The modest efficacy of these drugs implicates intrinsic or acquired resistance. Novel molecular agents inhibiting alternative targets to overcome anti-EGFR resistance in HNSCC are under investigation. Gene therapy and immunotherapy are also promising strategies to improve efficacy and reduce toxicity.

Expert opinion: To date, only six drugs have been FDA-approved for the treatment of head and neck cancer. Cetuximab is the only approved molecular targeting agent for HNSCC and despite ubiquitous expression of EGFR in HNSCC tumors, clinical responses are limited. Genetic and epigenetic characterization of HNSCC tumors, coupled with improved preclinical models, should facilitate the development of more effective drugs.

Keywords: cetuximab, chemotherapy, clinical trial, drugs resistance, epidermal growth factor receptor, gene therapy, head and neck cancer, immunotherapy, squamous cell carcinoma, The Cancer Genome Atlas


1. Background

Head and neck cancers comprise a spectrum of malignancies arising in the oral cavity, pharynx and larynx with squamous cell carcinoma representing the most common histology (~ 85%) [1]. Worldwide, head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer with an incidence of over 600,000 and over 350,000 deaths per year [2]. Of newly diagnosed patients, about two-thirds present with advanced-stage disease, usually with regional lymph node involvement [3], and 10% have distant metastases [4]. The most common predisposing factors include tobacco exposure and alcohol consumption. In addition, an increasing number of oropharyngeal cancers are linked with human papilloma virus (HPV) infection [5]. HNSCC treatment generally involves several modalities including surgery, radiotherapy (RT) and chemotherapy (CT) depending on the site of the primary tumor, TNM staging, expected oncological and functional outcomes and the treatment toxicities. Generally, single-modality treatment may be chosen for early stage disease while advanced stages require a multidisciplinary approach [1]. In the last few years, the integration of surgery, RT and CT has become the standard of care [1].

The US FDA to date has approved six agents for the treatment of HNSCC including five conventional CT drugs (cisplatin, methotrexate, 5-flourouracil...
Cetuximab, an epidermal growth factor receptor (EGFR) mAb, is currently the only FDA-approved EGFR targeting strategy for HNSCC. It is approved in three specific applications: in combination with radiation for LA disease, as a single agent for R/M disease after failure of platinum-based CT and in combination with platinum-based CT plus 5-FU for the first-line R/M HNSCC [14-16]. The National Comprehensive Cancer Network guidelines also suggest that cetuximab plus platinum (cisplatin or carboplatin) and 5-FU is a category one treatment option for patients with unresectable or R/M non-nasopharyngeal HNSCC [17]. Cetuximab is a chimeric human/murine IgG1 mAb, which binds with high affinity to EGFR. Its antitumor mechanisms include the inhibition of natural ligand-binding receptor activation, initiation of receptor endocytosis and the activation of antibody-dependent cell-mediated cytotoxicity (ADCC). It also inhibits DNA double-strand-break repair that contributes to RT and DNA damage-inducing CT resistance by preventing nuclear import of EGFR [18-21].

Drug resistance (intrinsic or acquired) is one of the major challenges in the current therapy of HNSCC. Despite widespread EGFR expression, many HNSCC tumors do not respond to EGFR-targeting therapies. Identification of predictive biomarkers to better select those patients who are likely to benefit from these costly treatments is likely to improve outcomes [22]. One major obstacle is the genetic heterogeneity of cancer, including HNSCC. Analysis of publically available databases that describe the genetic and epigenetic lesions in HNSCC, like The Cancer Genome Atlas (TCGA), is likely to provide valuable insight into the biology of this cancer [23-26].

This review focuses on the major drugs under clinical investigation in HNSCC treatment, including EGFR-targeted drugs and molecular agents inhibiting alternative targets.

2. Medical need

HNSCC is the sixth most common cancer in the world with an incidence of over 600,000 per year [2]. About two-thirds present with advanced-stage disease. For these patients, 5-year survival rates are < 50% [27]. Although conventional treatments have improved, survival rates for HNSCC have remained relatively stagnant over the past three decades [28], ignoring the intrinsic favorable prognosis in HPV-positive patients. The aggressive chemoradiation necessitated by advanced HNSCC disease often results in severe side effects (xerostomia, dysphagia, etc.) that compromise post-treatment quality of life [29]. Moreover, the existing cytotoxic chemotherapeutic agents are non-selective and considerable toxicity. Thus, there is an urgent need for new agents that can be safely integrated into current treatment regimens to improve both the tolerability and the efficacy. The only FDA-approved EGFR-targeted agent, cetuximab, shows improvement in overall survival (OS) for HNSCC patients when in combination of CT or RT. However, the RR as a single agent of cetuximab is consistently lower than 15% [30]. Therefore, novel molecular treatments in HNSCC are also needed in order to overcome drug resistance.

3. Existing treatment

3.1 Conventional treatment

Conventionally, HNSCC treatments include surgery, RT and CT. Surgery is a standard treatment for HNSCC and is frequently dependent on the anatomical site and extent of tumor and the desire to achieve organ preservation. Advances in reconstruction techniques make it possible for patients who need extensive surgical resections in LA-HNSCC and are substantially improved functional outcomes, even for the setting who need salvage surgery after failure of organ-preserving treatment. Neck dissection is usually carried out in primary surgical management or after chemoradiation when residual disease is suspected. Nowadays, attention has been gained for the emerging sentinel lymph node biopsy and its ability to reliably detect nodal metastasis in HNSCC. Moreover, advances in minimally invasive endoscopic laser or robotic techniques have reduced postoperative complication and is related to a better organ and functional preservation [1,4,31]. Nevertheless, even continued evolution in surgical techniques, surgery alone is accompanied by a high risk of relapse in LA-HNSCC, and combination with other...
Emerging drugs for head and neck cancer

3.2 Targeted treatment – cetuximab

Cetuximab, an EGFR mAb, is currently the only FDA-approved EGFR-targeting strategy for HNSCC. It is approved based on a milestone randomized Phase III trial comparing cetuximab in combination with high-dose RT (211 patients) versus high-dose RT alone (213 patients) in patients with LA-HNSCC [14]. Cetuximab was initiated at a loading dose of 400 mg/m² a week before RT, followed by 250 mg/m²/week during RT. The combination of cetuximab and RT significantly improved median OS (49.0 vs 29.3 months) and median progression-free survival (PFS; 17.1 vs 12.4 months) versus RT alone. It is noteworthy that in combination with cetuximab, the incidence of radiation-associated acute toxicities was not increased. Five-year survival rates were 45.6% for cetuximab/RT versus 36.4% for RT alone [42]. This beneficial effect was seen mainly in patients with oropharyngeal cancers, the primary site of HPV-associated HNSCC, and was less evident in patients with laryngeal or hypopharyngeal cancers. Improvement in OS was limited to patients with prominent acneiform rash (hazard ratio; 0.49), suggesting that the development of a rash may predict cetuximab responses.

A number of ongoing Phase III trials are attempting to expand the use of cetuximab in LA-HNSCC, including induction TPF regimen CT followed by cisplatin/RT versus cetuximab/RT (NCT00716391, NCT00999700) and cetuximab/RT versus carboplatin/5-FU/RT (NCT01233843). Another four-arm Phase III trial included RT/concomitant CT or RT/concomitant cetuximab with induction TPV versus RT/concomitant CT or RT/concomitant cetuximab, without induction TPV (NCT01086826). Although the final results have not been published, the latest report from a Phase III trial conducted by the Radiation Therapy Oncology Group 0522 investigating the addition of cetuximab to the radiation-cisplatin platform for LA-HNSCC demonstrated no significant improvement in 30-day mortality (1.8 vs 2.0%, respectively; p = 0.81), 3-year PFS (61.2 vs 58.9%, respectively; p = 0.76), 3-year OS (72.9 vs 75.8%, respectively; p = 0.32), locoregional failure (19.9 vs 25.9%, respectively; p = 0.97) or distant metastasis (13.0 vs 9.7%, respectively; p = 0.08) and higher local toxicity was observed in the cetuximab arm [43]. They concluded that adding cetuximab to radiation-cisplatin did not improve outcome and hence should not be prescribed routinely. Outcomes did not differ by EGFR expression. As with all treatment regimens, higher PFS and OS were observed in patients with HPV-associated HNSCC.
Cetuximab has also been evaluated as monotherapy or in combination with CT in patients with R/M platinum-refractory HNSCC. Four hundred and forty-two patients with R/M HNSCC in a Phase III EXTREME trial [16] were randomized to receive platinum-based therapy or in combination with cetuximab as a first-line palliative regimen. A significant benefit of additional cetuximab with an improvement in median OS from 7.4 to 10.1 months (p = 0.04) was reported. No increase of CT-associated toxicities was observed in the cetuximab-containing arm. Combined analysis of p16 and HPV in this trial shows that adding cetuximab to CT improved survival, irrespective of tumor p16 or HPV status [44]. Three Phase II studies also demonstrated the efficacy of cetuximab in combination with platinum-based CT as second-line treatment in patients with R/M HNSCC, who failed to respond to first-line platinum-based CT alone [15,45,46]. Reported RRs and median OS were 10 – 13% and 5 – 6 months, respectively. An indirect comparison of these three Phase II trials suggests that cetuximab has the potential to increase median OS by ~ 2 months [30].

Despite the fact that combination of cetuximab with RT improves OS and PFS in LA-HNSCC compared with RT alone, addition of cetuximab with platinum-based CT improves median OS to 10.1 months in R/M HNSCC, latest Phase III trial demonstrated that adding cetuximab to CRT did not gain improvement of outcomes. Plus, the RR with cetuximab as a single agent is consistently lower than 15% [30] due to unclear resistance mechanisms. Hence, a better understanding of the molecular mechanisms of resistance to cetuximab may provide insights in new drugs development and identifying predictive biomarkers to optimize treatment strategies and lead to personalized therapy [47].

4. Market review

The expenditure of cancer therapy in the USA was $27 billion in 1990, and expanded to $90 billion in 2008, and is projected to jump to $157 billion by 2020 [48]. Much of this growth can be attributed to targeted therapies, as the globally cost grew to $13 billion in 2006 compared with $1.3 billion in 2001 [49]. Cetuximab sales for HNSCC treatment accounted for 30 - 40% of the worldwide market with a revenue of > $2 billion in 2009 [28]. As the only FDA-approved biological agent for HNSCC, cetuximab is expected to sustain continuing sales growth in the foreseeable future. Globally, the cost of cancer therapy is now growing at 21% per year [49]. As cancer therapy continues shifting towards biological agents and increasingly personalized-tailoring regimens, the cost of these drugs is expected to increase considerably due to the high cost of biological agents compared with conventional chemotherapeutics. Personalized medicine market in the USA was estimated at $232 billion in 2009 and is expected to grow 11% annually, nearly doubling to > $450 billion by 2015 [48]. Accordingly, the overall size of the head and neck cancer drugs market is projected to increase.

5. Current research goals

Conventional RT and CT are non-selective and therapies have been developed to exploit unique tumor factors with the hope of improving efficacy and reducing toxicity. The only FDA-approved molecular targeted agent, cetuximab, shows a RR lower than 15% [30] as a single agent in HNSCC treatment. Other EGFR-targeted agents such as tyrosine kinase inhibitors (TKIs) have not demonstrated improved survival in unselected populations. Thus, a better understanding of both predictive biomarkers and mechanisms of resistance to EGFR-targeted agents may lead to strategies to overcome resistance, and identify alternative targets for HNSCC treatment. The primary goal in the development of new drugs is to increase efficacy and reduce toxicity. As only a small subset of patients respond to EGFR-targeted therapy, identification of predictive biomarkers to select HNSCC patients most likely to benefit from cetuximab is warranted. Advances in basic research and analysis of genomic and epigenomic databases, like TCGA, are likely to facilitate deeper understanding of HNSCC biology and guide therapeutic developments.

6. Scientific rationale

6.1 EGFR biology and EGFR-targeted therapy

The EGFR is a transmembrane glycoprotein belonging to the EGFR tyrosine kinase family, which consists of EGFR/human EGFR 1 (HER1)/ErbB1, HER2/neu/ErbB2, HER3/ErbB3, HER4/ErbB4. All the four family members contain an extracellular ligand-binding domain, membrane-spanning domain and a cytoplasmic tyrosine kinase domain [47]. Aberrant expression or activity of EGFR has been identified in many human epithelial cancers, including HNSCC. Activation of EGFR by different ligands leads to homo- or heterodimerization of EGFR with another receptor of the HER family, and autophosphorylation of tyrosine residues leads to the activation of downstream signaling cascades including the well-known MAPK, phosphatidylinositol-3-kinase (PI3K)/Akt and STAT pathways that control gene transcription, cell proliferation and anti-apoptotic signals [50]. These ligands can be divided into three groups. The first group specifically binds to EGFR and includes epidermal growth factor (EGF), TGF-α and amphiregulin. The second group binds to both EGFR and HER4 and includes epiregulin, β-cellulin and heparin-binding EGF. The third group is composed of the neuregulins 1 – 4 and only binds to HER3 and HER4 [47]. HER2 has no known ligand. HER3 is the only family member that has no intrinsic kinase activity but downstream signaling is readily achieved through heterodimerization [47]. Despite the fact that clinical trials of EGFR-targeted therapies have rarely demonstrated a correlation between EGFR overexpression and the efficacy of EGFR-targeted therapies, the early studies suggest that increased
EGFR expression and gene copy number correlate with poorer prognosis [51] and radioresistance [52] in HNSCC, which indicate EGFR as a drug target.

Current EGFR-targeted drugs can be classified as either mAbs or TKIs (Figure 1). Monoclonal antibodies (mAbs) are intravenously administered and block ligand-binding induced receptor activation by specifically binding to the EGFR. Oral TKIs can reversibly or irreversibly inhibit the binding of ATP to the intracellular domain of EGFR and abrogate downstream signaling [22].

6.2 Molecular mechanism of EGFR-targeted therapy resistance

Cetuximab has a RR of only 13% [50] as a single agent in HNSCC treatment. Other EGFR-targeted agents such as TKIs have not demonstrated improved survival in unselected populations. The low efficacy suggests that other molecular mechanisms may exist that modulate intrinsic (primary) or acquired (secondary) resistance of EGFR inhibition. Identifying the mechanisms of resistance to EGFR-targeted agents may lead to strategies to overcome resistance, and identify alternative targets for HNSCC treatment (Figure 1). Possible strategies to overcome anti-EGFR resistance in HNSCC include (but are not restricted to) the inhibition of other receptor or non-receptor tyrosine kinases (e.g., MET, IGF-1R, sarcoma-family kinase [Src]), abrogation of VEGF/VEGFR, inhibition of downstream mediators in the EGFR signaling stream (e.g., PI3K inhibitors) and gene therapy (e.g., wild-type p53 restoration and EGFR antisense DNA) [47,53-56].

7. Competitive environment

The main characteristics of the major drugs and compounds currently applied or under development for HNSCC treatment are summarized in Table 1.

7.1 mAbs

Zalutumumab is a high-affinity human IgG1 anti-EGFR mAb, especially effective at inducing ADCC. Being completely human-derived, it is predicted to have a low immunogenicity profile compared with cetuximab, thus minimizing the risk of hypersensitivity reactions and compromising treatment efficacy in prolonged use [57]. In a Phase III trial, zalutumumab plus best supportive care (BSC) was associated with a prolonged PFS over BSC alone (median 9.9 vs 8.4 weeks; p = 0.0012) in patients with incurable R/M HNSCC. However, this study did not meet its end point of improving OS (median 6.7 vs 5.2 months; p = 0.0648) [58]. A Phase III trial to determine whether zalutumumab as a component of primary curative RT or CRT increases locoregional control in HNSCC patients is ongoing (NCT00496652).

Panitumumab is a human IgG2 anti-EGFR mAb, which may not elicit ADCC as strongly as cetuximab, reducing the incidence of life-threatening hypersensitivity reactions [59]. In a Phase I study, panitumumab plus paclitaxel, carboplatin and intensity-modulated RT was a tolerable regimen and was associated with at least a partial response (PR) in all 19 LA-HNSCC patients [60]. In a Phase III trial (SPECTRUM), panitumumab plus standard platinum-based CT versus CT alone in R/M HNSCC did not significantly improve the median OS (11.1 vs 9.0 months; p = 0.14) but did improve median PFS (5.8 vs 4.6 months; p = 0.004) [61]. When the results were analyzed by HPV status, both PFS and OS benefits were observed in HPV-negative patients [61]. A randomized Phase III trial comparing panitumumab/RT with cisplatin/RT (NCT00820248) in LA-HNSCC is ongoing. Several ongoing Phase II trials are evaluating combination of panitumumab with CT for R/M HNSCC (NCT00756444), as second-line monotherapy for R/M HNSCC (NCT00446446), or in combination with postoperative CRT for LA-HNSCC (NCT00798655). A Phase II biomarker-focused evaluation in LA-HNSCC patients receiving a single dose of panitumumab prior to definitive therapy (surgery or RT) (NCT01305772) was terminated for low accrual.

Nimotuzumab is another humanized anti-EGFR mAb with a lower incidence of skin toxicity compared with cetuximab or panitumumab. In contrast to other anti-EGFR antibodies, the intrinsic properties of nimotuzumab requires bivalent binding for stable attachment to cellular surface, thus selectively binding to cells with moderate-to-high EGFR expression. For normal cells with low EGFR expression, cetuximab and panitumumab still have high avidity target binding because their higher affinity constants lead to increased toxicities. Nimotuzumab with lesser affinity binds with less avidity and only causes transient target-binding interactions. Therefore, it spares healthy cells and avoids severe dose-limiting toxicities. All anti-EGFR antibodies can bind with a similar higher avidity to the cells with moderate-to-high EGFR expression and no clinical evidence from studies with panitumumab or cetuximab suggests greater efficacy than nimotuzumab [62]. Nimotuzumab is approved for HNSCC in several countries outside the USA [62]. A non-randomized Phase II trial of nimotuzumab plus RT in LA-HNSCC described its tolerability and increasing OS with increasing doses [63]. Subsequently, in a double-blind randomized trial in LA-HNSCC (n = 106), nimotuzumab plus RT had a significantly higher complete response rate (CRR) than placebo plus RT (59.5 vs 34.2%; p = 0.038), and no cases of skin rash were observed in nimotuzumab-treated patients. Median OS was improved (12.5 vs 9.5 months; p = 0.0491) [64]. In a Phase IIb study of CRT alone or plus nimotuzumab in HNSCC, median survival in the CRT-alone arm was 22 versus > 30 months in the CRT plus nimotuzumab arm (p < 0.003) [65]. There was a significant relationship between EGFR expression and OS in patients who received nimotuzumab plus CRT (p = 0.02), although few studies have found a correlation between EGFR expression and response to EGFR-targeted therapies. Ongoing Phase III trials in LA-HNSCC are testing the addition of nimotuzumab to RT (NCT01345084) and to...
adjuvant CRT (NCT00957086). Moreover, ongoing Phase II trials may provide additional insights into the use of nimotuzumab when added to CT for incurable HNSCC (NCT01425736) and to CRT for LA-HNSCC (NCT01516996; NCT00702481).

A dual-targeting anti-EGFR mAb simultaneously blocks two receptors, *duligotuzumab* (a human IgG1 anti-EGFR/HER3 mAb, NCT01577173) [66,67], is being studied in early phase trials to overcome resistance to cetuximab. While these newer anti-EGFR mAbs are being investigated in an attempt to improve outcomes or reduce toxicity in HNSCC, no preclinical or clinical evidence to date demonstrates superiority with respect to cetuximab.

### 7.2 Tyrosine kinase inhibitors

Unlike the mAbs, the TKIs have been developed to target the tyrosine kinase domain of EGFRs and to inhibit downstream signaling, eventually blocking the proliferation of tumor cells.

#### 7.2.1 Reversible EGFR TKIs

*Gefitinib* is an oral small-molecule reversible EGFR TKI, and was the first TKI to reach Phase III investigation in HNSCC. However, due to recent negative study results, it is unlikely to be further developed [28]. In a Phase III trial, monotherapy of gefitinib 250 and 500 mg/day, or methotrexate 40 mg/m^2/week was compared in 486 recurrent HNSCC patients after either CRT or surgery [68]. The RR was 2.7, 7.6 and 3.9% for gefitinib.
**Table 1. Competitive environment table of the major drugs and compounds currently applied or under development for HNSCC treatment.**

<table>
<thead>
<tr>
<th>Compound</th>
<th>Company</th>
<th>Stage of development</th>
<th>Mechanism of action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cisplatin</td>
<td>Bristol-Myers Squibb (BMS)</td>
<td>Marketed</td>
<td>DNA synthesis inhibitor</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Lederle (now Pfizer)</td>
<td>Marketed</td>
<td>Thymidylate synthase inhibitor</td>
</tr>
<tr>
<td>5-Flourouracil</td>
<td>Simcere Pharmaceuticals</td>
<td>Marketed</td>
<td>DNA and RNA synthesis inhibitor</td>
</tr>
<tr>
<td>Bleomycin</td>
<td>PCI Biotech</td>
<td>Marketed</td>
<td>DNA inhibitor</td>
</tr>
<tr>
<td>Docetaxel</td>
<td>Sanofi</td>
<td>Marketed</td>
<td>Microtubule stimulant</td>
</tr>
<tr>
<td>Cetuximab</td>
<td>Eli Lilly, Bristol-Myers Squibb, Merck KGaA</td>
<td>Marketed</td>
<td>EGFR mAb</td>
</tr>
<tr>
<td>Zalutumumab</td>
<td>Genmab, MATOS Pharma</td>
<td>Phase III</td>
<td>EGFR mAb</td>
</tr>
<tr>
<td>Panitumumab</td>
<td>Amgen, Takeda</td>
<td>Phase III</td>
<td>Reversible EGFR TKI</td>
</tr>
<tr>
<td>Nimotuzumab</td>
<td>Center of Molecular Immunology, YM Biosciences</td>
<td>Phase III</td>
<td>Reversible dual EGFR/HER2 TKI</td>
</tr>
<tr>
<td>Duligotuzumab</td>
<td>Roche</td>
<td>Phase II</td>
<td>Dual EGFR/HER3 mAb</td>
</tr>
<tr>
<td>Gefitinib</td>
<td>AstraZeneca</td>
<td>Phase III</td>
<td>Reversible EGFR TKI</td>
</tr>
<tr>
<td>Erlotinib</td>
<td>OSI Pharmaceuticals (now Astellas)</td>
<td>Phase III</td>
<td>Reversible EGFR TKI</td>
</tr>
<tr>
<td>Lapatinib</td>
<td>GlaxoSmithKline</td>
<td>Phase III</td>
<td>Reversible dual EGFR/HER2 TKI</td>
</tr>
<tr>
<td>Afatinib</td>
<td>Boehringer Ingelheim</td>
<td>Phase III</td>
<td>Irreversible pan-HER TKI</td>
</tr>
<tr>
<td>Dacomitinib</td>
<td>Pfizer</td>
<td>Phase II</td>
<td>Irreversible pan-HER TKI</td>
</tr>
<tr>
<td>Ficlatuzumab</td>
<td>AVEO</td>
<td>Phase II</td>
<td>HGF mAb</td>
</tr>
<tr>
<td>Foretinib</td>
<td>Exelixis, GSK</td>
<td>Phase II</td>
<td>SSKI (include c-MET)</td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>Genentech (now Roche)</td>
<td>Phase III</td>
<td>Anti-VEGF mAb</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>Pfizer</td>
<td>Phase II</td>
<td>Multiple TKI</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>Bayer and Amgen</td>
<td>Phase II</td>
<td>Multiple TKI</td>
</tr>
<tr>
<td>Dasatinib</td>
<td>Bristol-Myers Squibb (BMS)</td>
<td>Phase II</td>
<td>Multiple TKI</td>
</tr>
<tr>
<td>BKM120 (Buparlisib)</td>
<td>Novartis</td>
<td>Phase II</td>
<td>PI3K inhibitor</td>
</tr>
<tr>
<td>BYL719 (Alpelisib)</td>
<td>Novartis</td>
<td>Phase II</td>
<td>PI3K inhibitor</td>
</tr>
<tr>
<td>PX-866</td>
<td>Oncothyreon</td>
<td>Phase II</td>
<td>PI3K inhibitor</td>
</tr>
<tr>
<td>Temsirolimus</td>
<td>American Home Products (AHP)</td>
<td>Phase II</td>
<td>mTOR kinase inhibitor</td>
</tr>
<tr>
<td>Everolimus</td>
<td>Novartis</td>
<td>Phase II</td>
<td>mTOR kinase inhibitor</td>
</tr>
<tr>
<td>Genticine</td>
<td>SiBiono GeneTech</td>
<td>Phase II</td>
<td>pS3 stimulant</td>
</tr>
<tr>
<td>SCH-58500</td>
<td>Canji (Schering-Plough; now Merck &amp; Co)</td>
<td>Phase III</td>
<td>pS3 stimulant</td>
</tr>
<tr>
<td>Advexin</td>
<td>Introgen Therapeutics</td>
<td>Phase III</td>
<td>pS3 stimulant</td>
</tr>
<tr>
<td>ONX-015 (Lontucirex)</td>
<td>Onyx Pharmaceuticals (now Amgen)</td>
<td>Phase III</td>
<td>pS3 stimulant</td>
</tr>
<tr>
<td>H-101</td>
<td>Shanghai Sunway Biotech</td>
<td>Phase III</td>
<td>pS3 stimulant</td>
</tr>
<tr>
<td>EGFR antisense DNA</td>
<td>University of Pittsburgh</td>
<td>Phase II</td>
<td>EGFR antisense DNA</td>
</tr>
<tr>
<td>Nivalentab</td>
<td>Ono and Medarex (Bristol-Myers Squibb)</td>
<td>Phase III</td>
<td>Programmed cell death-1 mAb</td>
</tr>
<tr>
<td>IRX-2</td>
<td>IRX Therapeutics</td>
<td>Phase II</td>
<td>Multi-cytokine immunostimulant</td>
</tr>
<tr>
<td>MAGE-A3</td>
<td>GlaxoSmithKline</td>
<td>Phase I</td>
<td>Peptide epitope vaccine (immunostimulant)</td>
</tr>
<tr>
<td>MAGE-A3 Human papilloma virus-16 vaccine</td>
<td>University of Maryland</td>
<td>Phase I</td>
<td>Peptide epitope vaccine (immunostimulant)</td>
</tr>
<tr>
<td>INO-3112</td>
<td>Inovio Pharmaceuticals</td>
<td>Phase VII</td>
<td>DNA vaccine (immunostimulant)</td>
</tr>
<tr>
<td>DNA vaccine</td>
<td>University of Pittsburgh</td>
<td>Phase I</td>
<td>DC vaccine (immunostimulant)</td>
</tr>
</tbody>
</table>

DC: Dendritic cell; HER: Human EGFR; HGF: Hepatocyte growth factor; HNSCC: Head and neck squamous cell carcinoma; IGF-1R: IGF-1 receptor; MET: Also called c-MET tyrosine kinase or HGF receptor; mTOR: Mammalian target of rapamycin; PI3K: Phosphatidylinositol-3-kinase; Src: Sarcoma-family kinase; SSKI: Spectrum selective kinase inhibitor; TKI: Tyrosine kinase inhibitor; VEGFR: VEGF receptor.
250, 500 mg/day or methotrexate, with no significant differences between either dose of gefitinib or methotrexate. Neither dose of gefitinib was associated with improved survival compared with methotrexate (5.6 vs 6.7 vs 6.0 months; gefitinib 250, 500 mg/day and methotrexate, respectively). In another Phase III trial [69], 270 patients with R/M HNSCC were randomized to receive docetaxel plus gefitinib or plus placebo. No difference in OS was observed (7.3 months docetaxel/ gefitinib vs 6.0 months docetaxel/placebo), although an unplanned subset analysis showed that gefitinib improved survival in patients younger than 65 years (median 7.6 vs 5.2 months; p = 0.04). *Erlotinib* is another oral, small-molecule, reversible EGFR TKI that has demonstrated efficacy in patients with HNSCC. Early Phase II trial showed tolerability and anti-tumor activity (overall objective RR was 4.3%) for erlotinib as monotherapy in R/M HNSCC [70]. However, another randomized Phase II trial [71] compared CRT plus erlotinib versus CRT alone and showed that complete response (CR) and PFS rates were not increased by the addition of erlotinib. Moreover, two Phase III trials of erlotinib, one as a component of first-line standard platinum containing CT for advanced HNSCC (NCT00448240) and the other as maintenance monotherapy after CRT or RT alone for resected HNSCC (NCT00412217), were terminated early for low accrual.

### 7.2.2 Dual and pan-Her TKIs

Heterodimerization of EGFR with other members of the HER family may be responsible for the limited activity of EGFR-targeted mAbs or TKIs. The ability to block more than just EGFR could therefore be of interest.

*Lapatinib* is an oral reversible dual EGFR and HER2 TKI. A randomized Phase II study assessed the activity and safety of CRT plus lapatinib followed by lapatinib maintenance treatment in 67 unresected LA-HNSCC and showed that lapatinib combined with CRT is well-tolerated with an increase in CRR (53 vs 36%) at 6 months post-CRT, and median PFS (55 vs 41%) at 18 months post-CRT compared with CRT plus placebo [72]. Another Phase II trial showed that a short-term course of lapatinib monotherapy (4 weeks) did not induce tumor apoptosis, but provided evidence of clinical activity (objective RR was 17 vs 0% placebo) in LA-HNSCC [73]. Conversely, a recently published Phase II trial of lapatinib as monotherapy in R/M HNSCC demonstrated no CR or PR, in either EGFR inhibitor-naive or refractory subjects [74].

A randomized Phase III trial is currently ongoing to study the combination of RT plus platinum-based CT with lapatinib or placebo in postoperative setting (NCT00424255). Other Phase II trials are testing the use of lapatinib with RT for LA-HNSCC who cannot tolerate CRT (NCT00490061), in combination with primary CRT in LA-HNSCC (NCT00387127), and in combination with CRT in HPV-negative patients (NCT01711658).

A new generation of TKIs, the irreversible small molecule pan-HER inhibitors, including afatinib and dacomitinib, have been developed. By covalently binding and irreversibly blocking multiple ErbB family kinases, sustained suppression of tumor growth may occur.

*Afaratinib* is a TKI that irreversibly inhibits EGFR (including EGFR vIII), HER2 and HER4 kinases. In an open-label, randomized, Phase II trial conducted in 43 centers, 124 patients with R/M HNSCC failed with platinum-based therapy, were randomized to receive afatinib 50 mg/day or cetuximab 250 mg/m²/week until disease progression or intolerable adverse events (stage I), with optional crossover (stage II) [75]. Antitumor activity of afatinib was comparable with cetuximab with tumor shrinkage 10.4 versus 5.4%, ORR 16.1% versus 6.5%, disease control rates 50 versus 56.5%, respectively. Median OS (55.9 vs 47.1 weeks, p = 0.78) was also comparable. In stage II, the disease control rate was 38.9% with afatinib and 18.8% with cetuximab, suggesting sustained clinical benefit from sequential treatment with afatinib and cetuximab and a lack of cross-resistance [75]. Afatinib is now under development in several Phase III clinical trials investigating a comparison of afatinib with methotrexate as second-line treatment after failure of platinum-based CT in R/M HNSCC (NCT01345682), evaluating afatinib versus placebo as maintenance therapy after definitive CRT (NCT01345669) or after postoperative CRT (NCT01427478) for LA-HNSCC with a starting dose of 40 mg (instead of 50 mg) based on safety evaluations.

A neoadjuvant afatinib window study conducted by the European Organisation for Research and Treatment of Cancer (NCT01538381) is ongoing to the pharmacodynamic activity of afatinib in the presurgical setting. *Dacomitinib* is another small irreversible pan-HER inhibitor (EGFR, HER2 and HER4 kinases), which was investigated as first-line treatment for R/M HNSCC in a Phase II trial [76] with a 12.7% PR rate and 12.1 weeks median PFS and 34.6% median OS. However, no evidence shows how it is compared with afatinib.

### 7.3 Other targeting agents investigated to overcome EGFR-targeted therapy resistance

#### 7.3.1 c-Met

c-MET is a transmembrane tyrosine receptor primarily expressed on epithelial cells, which can be activated after binding to hepatocyte growth factor (HGF) secreted by mesenchymal cells. This epithelial–mesenchymal interaction mediates downstream signaling through MAPK, PI3K, STAT3 and NF-kB [77] and is associated with tumor proliferation, invasion and angiogenesis when aberrantly activated. To date, HGF is the sole known ligand binding to c-MET. *Ficlatuzumab* is a humanized anti-HGF mAb that inhibits HGF-induced c-MET activation. Preclinical studies and clinical trials to date have demonstrated antitumoral activity and acceptable toxicity of ficlatuzumab [78-80]. A Phase Ib trial of ficlatuzumab in R/M HNSCC is ongoing to find the recommended Phase II dose of the combination of ficlatuzumab and cetuximab (NCT02277197). Amplification of the...
c-MET oncogene [81] leads to increased expression and activation of c-MET [82,83], which is related to EGFR inhibitors resistance, radiation resistance [84] and cisplatin resistance [85]. c-MET is overexpressed in 58 - 84% HNSCC [84,86] and c-MET mutations have been identified in HNSCC tumor tissues and cell lines [84]. Foretinib is an oral multikinase inhibitor of c-MET and the VEGF receptor 2 (VEGFR2). In a Phase II trial, foretinib (240 mg/day) was orally administered to 14 R/M HNSCC. Fifty percent of patients (7/14) showed stable disease, 43% of patients (6/14) experienced tumor shrinkage and two patients had prolonged disease stabilization for > 13 months [87].

7.3.2 IGF-1 receptor targeted agent
The IGF-1 receptor (IGF-1R) is overexpressed in HNSCC [88,89] and may heterodimerize with EGFR in HNSCC cells when stimulated by either IGF or EGF [89], activating downstream signaling pathways, which are associated with cell growth, proliferation, cell differentiation, anti-apoptotic signaling and angiogenesis. It has been reported that elevated IGF-1R expression is associated with benefit of gefitinib in HNSCC patients with postoperative CRT [90]. Although cumulative evidence implicates IGF-1R as a target for HNSCC treatment, investigation of figitumumab (a fully human mAb IgG2 subtype targeting the IGF-1R) in incurable HNSCC with progressive disease on platinum-based therapy in Phase II trials found no evidence of clinical activity [91].

7.3.3 VEGF/VEGFR-targeted agents
Angiogenesis is an important process for primary tumor growth, cell proliferation, invasiveness, metastasis and radiation resistance. It is understood that under hypoxic conditions, multiple growth factors are released by cancer cells, including the VEGF [92-94], VEGF-A is the most important member of the VEGF family, which mediates angiogenesis by binding to VEGFR1-3 [94]. In HNSCC, VEGF and VEGFR expression in tumor tissue is associated with worse prognosis [95,96]. Currently, the two dominant approaches to targeting angiogenesis are antibody-mediated inhibition of VEGF and small molecule inhibition of VEGFR tyrosine kinases [97]. Bevacizumab is a humanized anti-VEGF mAb that binds to all five isoforms of VEGF [98], reducing the total amount of circulating VEGF. A Phase II trial showed that the addition of bevacizumab to cisplatin plus IMRT did not increase toxicity in LA-HNSCC [99]. In another Phase II trial, combination of bevacizumab with cetuximab was well-tolerated and showed some activity in 46 R/M HNSCC patients [100]. The ORR, disease-control rate (DCR), median PFS and OS were 16, 73%, 2.8 and 7.5 months, respectively. However, in another Phase II trial investigating the addition of bevacizumab to pemtrexed in 40 R/M HNSCC patients, serious bleeding events occurred in 15% patients and were fatal in two patients [101]. A Phase III randomized trial comparing CT with or without bevacizumab in R/M HNSCC is ongoing (NCT00588770). Sunitinib is an oral TKI of VEGFRs, platelet-derived growth factor receptors (PDGF-Rs), Flt3 and c-kit tyrosine kinase. A Phase II trial was conducted in 38 HNSCC patients who had failed to respond to prior platinum therapy [102]. Only one PR was reported, which demonstrated modest activity in palliative HNSCC. In another Phase II trial [103], sunitinib (50 mg/day for 4 weeks in a 6-week cycle) was investigated in patients with incurable disease. Only one PR was observed in total 22 patients. No clinical activity was shown in another Phase II trial [104] with sunitinib monotherapy in R/M HNSCC and no further development of the drug is ongoing. Sorafenib is another multikinase inhibitor of VEGFR, PDGFR, Raf and c-kit kinase. Sorafenib monotherapy (400 mg three times a day continuously for a 28-day cycle) was investigated in a Phase II trial with 41 CT-naive R/M squamous cell carcinoma of the head and neck patients [105]. The estimated PR was 2%, the median PFS and OS were 4 and 9 months, respectively. Another Phase II trial comparing combination of sorafenib with cetuximab versus cetuximab alone is ongoing in refractory, R/M HNSCC patients (NCT00939627).

7.3.4 Src kinases inhibitor
Src kinases are intracellular tyrosine kinases that can affect cellular proliferation and survival by activation of STAT family of transcription factors, especially STAT3 [106]. Preclinical HNSCC models have demonstrated that inhibition of c-Src give rise to block invasion [107], induce apoptosis [108], blockage of DNA repair and EGFR nuclear translocation and sensitize HNSCC cell lines to radiation and enhance EGFR inhibition [109,110]. Dasatinib is a small molecule inhibitor of Src kinase. However, monotherapy of dasatinib failed to demonstrate activity in a Phase II trial with R/M HNSCC [111]. Of evaluated 12 patients, no OR was observed although 2 patients (16.7%) had stable disease at 8 weeks. As dasatinib has potential synergistic activity of anti-EGFR agents, addition of dasatinib to cetuximab in recurrent HNSCC who have received cetuximab-containing curative therapy in a Phase II trial (NCT01488318), to cetuximab and RT ± cisplatin in LA HNSCC in a Phase I/II trial (NCT00882583), and to erlotinib in a biomarker-focused evaluation for HNSCC with planned primary or salvage surgical resection (NCT00779389) are underway.

7.3.5 PI3K/Akt/mTOR pathway inhibitors
Activation of PI3K/Akt/mammalian target of rapamycin (mTOR) signaling plays a crucial role in the carcinogenesis of various human malignancies including HNSCC, independent from EGFR activation [112]. Consequently, alterations of this pathway might also play a role in resistance to anti-EGFR therapy, which makes this pathway attractive for molecular-oriented drug therapies. Three Phase II studies with PI3K inhibitors, BKM120 as monotherapy in patients with platinum refractory R/M disease (NCT01737450), BYL719 plus cetuximab versus cetuximab alone (NCT01602315) and PX-866 plus docetaxel versus docetaxel alone
Gene therapy

Targeting the specific genetic alterations responsible for carcinogenesis and cancer progression is an attractive strategy for developing more effective anticancer therapeutics and reducing treatment-related toxicity. Gene therapy is generally delivered locally and HNSCC is ideally suited for gene therapy because lesions are readily accessible for injection or application of the agent. Several genetic alterations of tumor suppressor genes have been reported in the head and neck cancer including mutation of TP53, the retinoblastoma gene, p16 (CDKN2A) and PTEN [53,116]. Since the high incidence of TP53 mutation (69.8%) and the protein p53 plays an important role in cell cycle and in apoptosis, gene therapy approaches delivering p53 have been tested in HNSCC by direct injection of an adenoviral vector expressing wild-type p53 gene (Adp53), mostly in the USA and the People’s Republic of China [118].

Gendicine (SBN-1) is the first Adp53-based gene therapy product in the world approved by the State FDA of the People’s Republic of China (SFDA) for the treatment of HNSCC in 2003, and was formally launched in 2004. It is a recombinant human serotype 5 adenovirus with the E1 region replaced by a human wild-type p53 expression cassette, and has been tested in clinical trials for the treatment of patients with various cancers [118]. The antitumor activities of the expressed wild-type p53 gene include triggering apoptotic pathways, activating immune response factors such as natural killer (NK) cells, inhibiting DNA repair and anti-apoptotic functions and blocking the transcription of survival signals [118]. In a Phase I clinical trial, Gendicine plus surgery was administered to 12 patients with advanced laryngeal cancer [119]. The 3-year relapse rate in Gendicine plus surgery arm was 0 versus 30% in surgery-alone arm. Three Phase II/III clinical trials demonstrated that Gendicine in combination with RT showed synergistic effects in HNSCC [120-122].

Other Adp53 vectors such as SCH-585000 (CANJL, Inc, San Diego, CA, USA) and Advexin (INGN-201; Introgen Therapeutics, Inc, Austin, TX, USA) have been developed and have been used in various clinical trials [123,124]. Although a few remarkable cases have been reported, Advexin did not show convincing results and therefore was not approved by the FDA [118]. Due to the low transduction rate of p53 gene introduction via Adp53 vector, several types of cancer-specific p53-expressing conditionally replicating adenovirus vectors (known as conditionally replicating Adp53 [CRAdp53] vectors), which can induce higher p53 expression and stronger antitumor effects have been developed [125].

ONYX-015 is currently the most extensively evaluated E1B gene deleted CRAdp53 vector, which can selectively proliferate in p53 mutant and induce adenovirus-mediated cytotoxicity, but not in p53 wild-type cells. Although this concept is controversial, ONYX-015 combined with CT is more effective than CT alone for patients with recurrent HNSCC [126]. Another Phase II trial reported modest antitumor activity in HNSCC (10 – 14%) [127].

H-101 is a recombinant adenovirus with a total deletion of E1B gene similar to ONYX-015, and an additional partial E3 region deletion, which may enhance the safety profile of the administered adenovirus [128]. The SFDA approved H-101, especially for advanced nasopharyngeal carcinoma in combination with cisplatin and 5-FU in 2005. A Phase III randomized clinical trial compared effects of intratumoral H-101 injection plus PF regimen CT versus PF regimen CT alone in HNSCC and squamous cell carcinoma of esophagus, the ORR in H-101 plus PF was 78.8 versus 39.6% in PF-alone group (p = 0.000) [129]. Until now, only Gendicine and H-101 have been approved (SFDA), and both Adp53 and CRAdp53 vectors are not widely used.

In addition to delivering a tumor suppressor gene like p53, gene therapy can also be used to target oncogenes using antisense or siRNA strategies. EGFR antisense DNA therapy completed Phase I testing in HNSCC and a Phase II trial is ongoing (NCT00903461) [130,131]. The Phase I trial achieved a 29% clinical response and intratumoral EGFR antisense was safe and resulted in antitumor activity in patients with advanced HNSCC. Baseline levels of high EGFR and low STAT3 may be associated with antitumor effects. While effective to date, local delivery, even in HNSCC, remains a challenging strategy to employ in most clinical settings.

Immunotherapy

Immunotherapy is a promising area for HNSCC therapy as it mobilizes the immune system with limited effects on normal tissue, to target cancer cells that express tumor-specific antigens. HNSCC patients often present with a suppressed immune system, featuring dysregulation of immune-competent cells and cytokines [132-134]. As innate and adaptive immunity play an important role in HNSCC pathogenesis, it is likely that the development of immunotherapeutic approaches will prove promising [135]. Compared with the traditional chemotherapies, immunotherapy is more specific, generally less toxic and has the potential for inducing memory responses that could provide long-term tumor immune surveillance. Immunotherapy may decrease the incidence of relapses and increase the long-term disease-free survival via
Emerging drugs for head and neck cancer

continuous elimination of cancer cells by the primed immune system [116]. Immunotherapies can be classified into specific and non-specific immunotherapies. Specific immunity encompasses T cells and antibodies specifically recognizing and engaging a target while non-specific immunity includes antigen unspecified macrophages, dendritic cells (DC), NK cells and a multitude of factors and cytokines. Several immune-modulating agents have been tested in HNSCC patients [135]. These include below mentioned non-specific immune agents targeting specific tumor antigens and vaccine candidates based on different types of antigenic stimuli.

7.3.7.1 Anti-programmed cell death-1 antibody
Programmed death ligand-1 (PDL-1) is a ligand of the B7 superfamily expressed on tumor cells that inhibits T-lymphocyte function [137]. Programmed cell death-1 (PD-1), the receptor for PDL-1, is preferentially expressed on apoptotic cells. Binding of PDL-1 with PD-1 on T cells inhibits TCR-mediated IL-2 activation and T-cell proliferation signal [138]. Tumor infiltrating lymphocytes (TILs) that represent the host’s immune response to a malignant tumor are also part of this dynamic. PDL-1 expressed by HNSCC cells was found to correlate with decreased intratumoral TILs [139]. A Phase III trial investigating this emerging anti-PD-1 (nivolumab) versus cetuximab/methotrexate/docetaxel in R/M platinum-refractory HNSCC is ongoing (NCT02105636).

7.3.7.2 Other immunotherapeutic agents
Other immunotherapeutic agents are also in development for HNSCC. A Phase II trial showed that a multi-cytokine immunotherapy regimen (IFN-2) delivered in combination with cyclophosphamide, indomethacin and zinc followed by surgery in resectable HNSCC was well tolerated (NCT00210470) [140]. In addition, various ongoing Phase I–II trials are testing therapeutic vaccine strategies including peptide-based vaccines (NCT00257738, NCT00704041), a DNA vaccine (NCT02163057) and a DC vaccine (NCT00404339). The most effective immunotherapeutic regimen has yet to be defined in HNSCC.

8. Potential development issues
As is common in cancer therapy, a significant problem in the development of EGFR-targeted HNSCC therapies is the emergence of treatment resistance. Many HNSCC patients do not respond to EGFR inhibitor therapy (intrinsic resistance), and the majority of the patients who do achieve a clear tumor response to EGFR inhibitors will eventually manifest disease progression (acquired resistance) [47]. The elucidation of mechanisms of resistance to targeted therapies may provide valuable insights to improve outcomes by identifying new potential drugs as well as enabling rational combinations of molecular targeted therapies. The mechanism may include, but not restricted to, expression of other redundant receptor tyrosine kinase (i.e., HER2, MET) and activation of alternative or downstream pathways. For example, HER2 and HER3 have been linked to gefitinib resistance in HNSCC preclinical models [141]. c-MET is overexpressed in ~ 80% HNSCC and related to resistance to EGFR inhibitors and conventional RT and CT [84-86]. PI3K pathway can be activated by either receptor tyrosine kinase or via PIK3CA mutations or PTEN loss and play a role in resistance to anti-EGFR therapy [53]. MET inhibitors and PI3K inhibitors are under clinical investigation to overcome the resistance to anti-EGFR therapy. Such studies have the potential to improve patient outcome and may yield new insights into mechanisms of resistance, leading to opportunities for the design of rational combination therapies. Multi-target agents, such as irreversible pan-HER inhibitor afatinib currently in clinical trials, may also abrogate anti-EGFR resistance.

The second problem in the development of molecular targeted therapies is the lack of predictive biomarkers for the response to the treatment. The high mutational heterogeneity of HNSCC suggests that no single targeted inhibitor is likely to benefit a large percentage of patients [117]. As such, the identification of responsive cases to existing agents may be necessary in order to identify novel predictive biomarkers. To date, the only predictive clinical marker for response to cetuximab is the severity of skin rash, which is correlated with outcome in HNSCC [42]. Patients who developed a moderate or severe rash had an increased median OS compared with those who had a mild or no rash (68.8 vs 25.6 months). Higher EGFR expression was thought to be a predictor of better response to anti-EGFR treatment. However, although EGFR overexpression has been linked to better response to conventional treatment [52], increased EGFR in tumor cells to date has not been demonstrated to predict better response to EGFR-targeted therapies in HNSCC. Conversely, activating EGFR mutations in lung cancer has been demonstrated to predict response to EGFR TKIs [142]. KRAS mutations which are frequent in colorectal cancer have also been shown to predict response to cetuximab [143], but these mutations are rare in HNSCC ranging from 0 to 9.1% [56]. HPV-positive HNSCC has been demonstrated to have better outcomes and improved survival compared with the HPV-negative patients [144]. This difference may be due to fewer genetic mutations occurring in HPV-positive cancers [145]. Thus, stratifying HNSCC patients with respect to HPV status into two groups seems warranted in clinical trials investigating molecular targeted therapy. However, more clinical benefit was observed in HPV-positive patients with cetuximab regimen treatment [43], while the HPV-negative patients were more likely to benefit from panitumumab regimen treatment [61]. Further studies investigating the predictive value of HPV status are warranted.

Recently, four whole-exome sequencing studies conducted on approximate 190 HNSCC specimens provided insights into the molecular progression of HNSCC [145-148]. More recently, several hundred additional tumors have now been
analyzed by the TCGA project [149], affording the opportunity to utilize the genetic database of HNSCC in a large number of primary tumor. HNSCC appears to be generally driven by loss-of-function of tumor suppressors such as TP53, CDKN2A, CASP8 and NOTCH1, which may account for the unsatisfactory results of anti-EGFR therapy to date.

9. Conclusion

The existing CT agents approved for HNSCC therapy are non-selective and associated with considerable toxicity. Cetuximab is most likely to be effective in an as yet, incompletely defined subgroup of HNSCC patients. New EGFR mAbs are being investigated in an attempt to improve outcome and/or reduce toxicity. The clinical development of EGFR TKIs such as erlotinib and gefitinib has been limited by modest results in unselected HNSCC populations. It is expected that the second generation of TKIs with irreversible binding and dual/pan-HER-targeted functionality may prove more efficacious. Although some patients benefit from anti-EGFR therapy in HNSCC, the majority of tumors exhibit intrinsic or acquired resistance. Therefore, a better understanding of the molecular mechanisms of resistance is crucial. Strategies to overcome resistance to anti-EGFR therapeutics are being tested in clinical trials and may provide much-needed improvements in patient outcomes. These strategies include (but are not restricted to) the inhibition of other receptor or non-receptor tyrosine kinases, abrogation of VEGF/VEGFR, inhibition of downstream mediators in the EGFR signaling stream and gene therapy. Immunotherapy targeting cancer cells that express tumor-specific antigens, such as PD-1, with limited effects on normal tissue also represents a promising strategy.

Bibliography

Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers.


10. Expert opinion

Key findings to date in HNSCC therapy suggest that the disease is heterogeneous and that increased understanding of the biologic underpinnings of key subgroups will help guide therapy. High EGFR expression is generally a poor prognostic factor and contributed to the clinical development of cetuximab. However, most studies have failed to identify EGFR expression or gene copy number as a predictive biomarker of clinical response to EGFR-targeted therapies. Cetuximab is FDA-approved for both newly diagnosed and R/M HNSCC, although the modest benefits of adding this agent to standard chemoradiation regimens has limited its use worldwide. Ongoing trials are investigating cetuximab in combination with other molecular targeted agents that have generally been selected based on preclinical evidence implicating the target in cetuximab resistance. HPV-associated HNSCC represents a defined subgroup, which is generally associated with improved prognosis. In the absence of HPV-selective therapies, ongoing studies are generally exploring de-intensification of standard regimens for HPV-positive HNSCC. Ultimately, judicious selection of preclinical models will help to define predictive biomarkers and guide emerging therapies.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.
Emerging drugs for head and neck cancer

13. Pai CH, Relling MV. Can the genotoxicity of chemotherapy be predicted? Lancet 2004;364:917-18
31. Cetuximab as monotherapy with a low response rate.
41. Agulnik M. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med Oncol 2012;29:2481-91
42. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a
phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21–8


Adding cetuximab to concurrent chemoradiotherapy (CRT) did not improve outcome.


Combination of panitumumab to chemotherapy (CT) did not significantly improve the median overall survival (OS) versus CT alone in recurrent/metastasis (R/M) head and neck squamous cell carcinoma (HNSCC).


68. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the
Emerging drugs for head and neck cancer

- **Randomized trial in R/M HNSCC with no observed benefit with gefitinib in comparison with methotrexate.**


- **Combination of gefitinib to docetaxel did not increase OS.**


- **Adding erlotinib to CRT did not gain benefit.**


- **Very limited activity of lapatinib as monotherapy in R/M setting.**


- **Comparison between cetuximab and afatinib and possible reversion of resistance with crossover therapy.**


95. Kyraz PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma:


Emerging drugs for head and neck cancer

Yihui Wan 1,2,3 & Jennifer R Grandis 1,3,4,5,6

Affiliation
1Author for correspondence
2Sun Yat-Sen University and The First Affiliated Hospital of Sun Yat-Sen University, Department of Otolaryngology, Guangzhou, Guangdong, PR China
3Sun Yat-Sen University and Otolaryngology Institute of Sun Yat-Sen University, Guangzhou, Guangzhou, PR China
4University of Pittsburgh and University of Pittsburgh School of Medicine, Department of Otolaryngology, Pittsburgh, PA, USA
5University of Pittsburgh and University of Pittsburgh School of Medicine, Department of Pharmacology, Pittsburgh, PA, USA
6Eye and Ear Institute, 200 Lothrop St., Suite 500, Pittsburgh, PA, USA
7University of California, Clinical and Translational Science Institute, Department of Otolaryngology-Head and Neck Surgery, San Francisco, CA, USA

Tel: +1 415 514 8084; Fax: +1 412 383 5409; E-mail: Jennifer.grandis@ucsf.edu